Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2)

DNA Repair

Volumn 19, Issue , 2014, Pages 114-129

  Pommier, Yves ^a   Huang, Shar yin N ^a   Gao, Rui ^a   Das, Benu Brata ^a,b   Murai, Junko ^a,c   Marchand, Christophe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DEPARTMENT OF MATERIALS SCIENCE   (India)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Homologous recombination (HR); Non homologous end joining (NHEJ); Poly(ADPribose) polymerases (PARP); Topoisomerases

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BLEOMYCIN; CYTARABINE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TEMOZOLOMIDE; TOPOTECAN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TYROSYL DNA PHOSPHODIESTERASE 1; TYROSYL DNA PHOSPHODIESTERASE 2; UNCLASSIFIED DRUG; XRCC1 PROTEIN; NUCLEAR PROTEIN; PHOSPHODIESTERASE; TDP1 PROTEIN, HUMAN; TDP2 PROTEIN, HUMAN; TOP1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; VIRUS RNA;

ARTICLE; CATALYSIS; CELL NUCLEUS; DNA CLEAVAGE; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME STRUCTURE; EXCISION REPAIR; HUMAN; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; RNA CLEAVAGE; RNA VIRUS; SIGNAL TRANSDUCTION; VIRUS GENOME; ANIMAL; BOVINAE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASMS; PATHOGENICITY; PICORNAVIRIDAE;

BOVINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CATTLE; DNA END-JOINING REPAIR; DNA TOPOISOMERASES, TYPE I; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PHOSPHORIC DIESTER HYDROLASES; PICORNAVIRIDAE; RNA, VIRAL; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84902083476     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2014.03.020     Document Type: Article

References (203)

1. Pommier Y., Leo E., Zhang H., Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010, 17:421-433.
2. Seol Y., Zhang H., Pommier Y., Neuman K.C. A kinetic clutch governs religation by type IB topoisomerases and determines camptothecin sensitivity. Proc. Nat. Acad. Sci. U.S.A. 2012, 109:16125-16130.
3. Schoeffler A.J., Berger J.M. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q. Rev. Biophys. 2008, 41:41-101.
4. Wu L., Davies S.L., North P.S., Goulaouic H., Riou J.-F., Turley H., Gatter K.C., Hickson I.D. The Bloom's syndrome gene product interacts with topoisomerase III. J. Biol. Chem. 2000, 275:9636-9644.
5. Plank J.L., Wu J., Hsieh T.S. Topoisomerase IIIalpha and Bloom's helicase can resolve a mobile double Holliday junction substrate through convergent branch migration. Proc. Nat. Acad. Sci. U.S.A. 2006, 103:11118-11123.
6. Chen S.H., Wu J., Hsieh T.S. Essential functions of topoisomerase III alpha in the nucleus and mitochondria. DNA Topoisomerases and Cancer 2012, 103-117. Springer, New York, NY. Y. Pommier (Ed.).
7. Stoll G., Pietilainen O.P., Linder B., Suvisaari J., Brosi C., Hennah W., Leppa V., Torniainen M., Ripatti S., Ala-Mello S., Plottner O., Rehnstrom K., Tuulio-Henriksson A., Varilo T., Tallila J., Kristiansson K., Isohanni M., Kaprio J., Eriksson J.G., Raitakari O.T., Lehtimaki T., Jarvelin M.R., Salomaa V., Hurles M., Stefansson H., Peltonen L., Sullivan P.F., Paunio T., Lonnqvist J., Daly M.J., Fischer U., Freimer N.B., Palotie A. Deletion of TOP3beta, a component of FMRP-containing mRNPs, contributes to neurodevelopmental disorders. Nat. Neurosci. 2013, 16:1228-1237.
8. Xu D., Shen W., Guo R., Xue Y., Peng W., Sima J., Yang J., Sharov A., Srikantan S., Yang J., Fox D., Qian Y., Martindale J.L., Piao Y., Machamer J., Joshi S.R., Mohanty S., Shaw A.C., Lloyd T.E., Brown G.W., Ko M.S., Gorospe M., Zou S., Wang W. Top3beta is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation. Nat. Neurosci. 2013, 16:1238-1247.
9. Huang H.S., Allen J.A., Mabb A.M., King I.F., Miriyala J., Taylor-Blake B., Sciaky N., Dutton J.W., Lee H.M., Chen X., Jin J., Bridges A.S., Zylka M.J., Roth B.L., Philpot B.D. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 2012, 481:185-189.
10. Powell W.T., Coulson R.L., Gonzales M.L., Crary F.K., Wong S.S., Adams S., Ach R.A., Tsang P., Yamada N.A., Yasui D.H., Chedin F., Lasalle J.M. R-loop formation at Snord116 mediates topotecan inhibition of Ube3a-antisense and allele-specific chromatin decondensation. Proc. Nat. Acad. Sci. U.S.A. 2013, 110:13938-13943.
11. Lindahl T., Nyberg B. Rate of depurination of native deoxyribonucleic acid. Biochemistry 1972, 11:3610-3618.
12. Boiteux S., Jinks-Robertson S. DNA repair mechanisms and the bypass of DNA damage in Saccharomyces cerevisiae. Genetics 2013, 193:1025-1064.
13. Kim N., Huang S.Y., Williams J.S., Li Y.C., Clark A.B., Cho J.E., Kunkel T.A., Pommier Y., Jinks-Robertson S. Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science 2011, 332:1561-1564.
14. Sekiguchi J., Shuman S. Site-specific ribonuclease activity of eukaryotic DNA topoisomerase I. Mol. Cell 1997, 1:89-97.
15. Sparks J.L., Chon H., Cerritelli S.M., Kunkel T.A., Johansson E., Crouch R.J., Burgers P.M. RNase H2-initiated ribonucleotide excision repair. Mol. Cell 2012, 47:980-986.
16. Pourquier P., Pilon A., Kohlhagen G., Mazumder A., Sharma A., Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps: importance of DNA end phosphorylation and camptothecin effects. J. Biol. Chem. 1997, 272:26441-26447.
17. Pommier Y., Marchand C. Interfacial inhibitors: targeting macromolecular complexes. Nat. Rev. Drug Discovery 2012, 11:25-36.
18. Nitiss J., Wang J.C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Nat. Acad. Sci. U.S.A. 1988, 85:7501-7505.
19. Bjornsti M.-A., Benedetti P., Viglianti G.A., Wang J.C. Expression of human DNA topoisomerase I in Yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res. 1989, 49:6318-6323.
20. Miao Z.H., Player A., Shankavaram U., Wang Y.H., Zimonjic D.B., Lorenzi P.L., Liao Z.Y., Liu H., Shimura T., Zhang H.L., Meng L.H., Zhang Y.W., Kawasaki E.S., Popescu N.C., Aladjem M.I., Goldstein D.J., Weinstein J.N., Pommier Y. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res. 2007, 67:8752-8761.
21. Jarvinen T.A., Liu E.T. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Curr. Cancer Drug Targets 2006, 6:579-602.
22. Pommier Y., Pourquier P., Urasaki Y., Wu J., Laco G. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist. Update 1999, 2:307-318.
23. Murai J., Huang S.-y.N., Das B.B., Renaud A., Zhang Y., Doroshow J.H., Ji J., Takeda S., Pommier Y. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012, 72:5588-5599.
24. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6:789-802.
25. Holm C., Covey J.M., Kerrigan D., Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 1989, 49:6365-6368.
26. Hsiang Y.-H., Liu L.F., Wall M.E., Wani M.C., Nicholas A.W., Manikumar G., Kirschenbaum S., Silber R., Potmesil M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res. 1989, 49:4385-4389.
27. Maede Y., Shimizu H., Fukushima T., Kogame T., Nakamura T., Miki T., Takeda S., Pommier Y., Murai J. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel. Mol. Cancer Ther. 2014, 13:214-220.
28. Huang S.Y., Pommier Y., Marchand C. Tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibitors. Expert Opin. Ther. Pat. 2011, 21:1285-1292.
29. Zhang Y.W., Regairaz M., Seiler J.A., Agama K.K., Doroshow J.H., Pommier Y. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res. 2011, 39:3607-3620.
30. Wu J., Liu L.F. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res. 1997, 25:4181-4186.
31. Koster D.A., Palle K., Bot E.S., Bjornsti M.A., Dekker N.H. Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 2007, 448:213-217.
32. Sordet O., Redon C.E., Guirouilh-Barbat J., Smith S., Solier S., Douarre C., Conti C., Nakamura A.J., Das B.B., Nicolas E., Kohn K.W., Bonner W.M., Pommier Y. Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep. 2009, 10:887-893.
33. Pommier Y., Zwelling L.A., Mattern M.R., Erickson L.C., Kerrigan D., Schwartz R., Kohn K.W. Effects of dimethyl sulfoxide and thiourea upon intercalator-induced DNA single-strand breaks in mouse leukemia (L1210) cells. Cancer Res. 1983, 43:5718-5724.
34. Long B.H., Musial S.T., Brattain M.G. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. Biochemistry 1984, 23:1183-1188.
35. Ban Y., Ho C.W., Lin R.K., Lyu Y.L., Liu L.F. Activation of a novel ubiquitin-independent proteasome pathway when RNA polymerase II encounters a protein roadblock. Mol. Cell Biol. 2013, 33:4008-4016.
36. Long B.H., Musial S.T., Brattain M.G. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res. 1985, 45:3106-3112.
37. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem. Biol. 2013, 8:82-95.
38. Zwelling L.A., Michaels S., Erickson L.C., Ungerleider R.S., Nichols M., Kohn K.W. Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. Biochemistry 1981, 20:6553-6563.
39. Yang S.W., Burgin A.B., Huizenga B.N., Robertson C.A., Yao K.C., Nash H.A. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc. Nat. Acad. Sci. U.S.A. 1996, 93:11534-11539.
40. Pouliot J.J., Yao K.C., Robertson C.A., Nash H.A. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. Science 1999, 286:552-555.
41. Pouliot J.J., Robertson C.A., Nash H.A. Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae. Genes Cells 2001, 6:677-687.
42. Zhang H., Barcelo J.M., Lee B., Kohlhagen G., Zimonjic D.B., Popescu N.C., Pommier Y. Human mitochondrial topoisomerase I. Proc. Nat. Acad. Sci. U.S.A. 2001, 98:10608-10613.
43. Das B.B., Dexheimer T.S., Maddali K., Pommier Y. Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria. Proc. Nat. Acad. Sci. U.S.A. 2010, 107:19790-19795.
44. El-Khamisy S.F. To live or to die: a matter of processing damaged DNA termini in neurons. EMBO Mol. Med. 2011, 3:78-88.
45. Murai J., Huang S.Y., Das B.B., Dexheimer T.S., Takeda S., Pommier Y. Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells. J. Biol. Chem. 2012, 287:12848-12857.
46. Banerjee B., Roy A., Sen N., Majumder H.K. A tyrosyl DNA phosphodiesterase 1 from kinetoplastid parasite Leishmania donovani (LdTdp1) capable of removing topo I-DNA covalent complexes. Mol. Microbiol. 2010, 78:119-137.
47. El-Khamisy S.F., Saifi G.M., Weinfeld M., Johansson F., Helleday T., Lupski J.R., Caldecott K.W. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 2005, 434:108-113.
48. Interthal H., Chen H.J., Kehl-Fie T.E., Zotzmann J., Leppard J.B., Champoux J.J. SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. EMBO J. 2005, 24:2224-2233.
49. Miao Z.H., Agama K., Sordet O., Povirk L., Kohn K.W., Pommier Y. Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. DNA Repair (Amst.) 2006, 5:1489-1494.
50. Gao R., Das B.B., Chatterjee R., Abaan O.D., Agama K., Matuo R., Vinson C., Meltzer P.S., Pommier Y. Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel. DNA Repair (Amst.) 2014, 13:1-9.
51. Katyal S., el-Khamisy S.F., Russell H.R., Li Y., Ju L., Caldecott K.W., McKinnon P.J. TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo. EMBO J. 2007, 26:4720-4731.
52. Hirano R., Interthal H., Huang C., Nakamura T., Deguchi K., Choi K., Bhattacharjee M.B., Arimura K., Umehara F., Izumo S., Northrop J.L., Salih M.A., Inoue K., Armstrong D.L., Champoux J.J., Takashima H., Boerkoel C.F. Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?. EMBO J. 2007, 26:4732-4743.
53. Alagoz M., Wells O.S., El-Khamisy S.F. TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy. Nucleic Acids Res. 2014, 42:3089-3103.
54. Nilsen L., Forstrom R.J., Bjoras M., Alseth I. AP endonuclease independent repair of abasic sites in Schizosaccharomyces pombe. Nucleic Acids Res. 2012, 40:2000-2009.
55. Vance J.R., Wilson T.E. Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage. Proc. Nat. Acad. Sci. U.S.A. 2002, 99:13669-13674.
56. Debéthune L., Kohlhagen G., Grandas A., Pommier Y. Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. Nucleic Acids Res. 2002, 30:1198-1204.
57. Raymond A.C., Staker B.L., Burgin A.B. Substrate specificity of tyrosyl-DNA phosphodiesterase I (Tdp1). J. Biol. Chem. 2005, 280:22029-22035.
58. Interthal H., Chen H.J., Champoux J.J. Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. J. Biol. Chem. 2005, 280:36518-36528.
59. Interthal H., Champoux J.J. Effects of DNA and protein size on substrate cleavage by human tyrosyl-DNA phosphodiesterase 1. Biochem. J. 2011, 436:559-566.
60. Nitiss K.C., Malik M., He X., White S.W., Nitiss J.L. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. Proc. Nat. Acad. Sci. U.S.A. 2006, 103:8953-8958.
61. Liu C., Pouliot J.J., Nash H.A. Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1. Proc. Nat. Acad. Sci. U.S.A. 2002, 99:14970-14975.
62. Inamdar K.V., Pouliot J.J., Zhou T., Lees-Miller S.P., Rasouli-Nia A., Povirk L.F. Conversion of phosphoglycolate to phosphate termini on 3' overhangs of DNA double strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1. J. Biol. Chem. 2002, 277:27162-27168.
63. Zhou T., Lee J.W., Tatavarthi H., Lupski J.R., Valerie K., Povirk L.F. Deficiency in 3'-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1). Nucleic Acids Res. 2005, 33:289-297.
64. Zhou T., Akopiants K., Mohapatra S., Lin P.-S., Valerie K., Ramsden D.A., Lees-Miller S.P., Povirk L.F. Tyrosyl-DNA phosphodiesterase and the repair of 3'-phosphoglycolate-terminated DNA double-strand breaks. DNA Repair (Amst.) 2009, 8:901-911.
65. Lebedeva N.A., Rechkunova N.I., Lavrik O.I. AP-site cleavage activity of tyrosyl-DNA phosphodiesterase 1. FEBS Lett. 2011, 585:683-686.
66. El-Khamisy S.F., Katyal S., Patel P., Ju L., McKinnon P.J., Caldecott K.W. Synergistic decrease of DNA single-strand break repair rates in mouse neural cells lacking both Tdp1 and aprataxin. DNA Repair (Amst.) 2009, 8:760-766.
67. Ben Hassine S., Arcangioli B. Tdp1 protects against oxidative DNA damage in non-dividing fission yeast. EMBO J. 2009, 28:632-640.
68. Dexheimer T.S., Stephen A.G., Fivash M.J., Fisher R.J., Pommier Y. The DNA binding and 3'-end preferential activity of human tyrosyl-DNA phosphodiesterase. Nucleic Acids Res. 2010, 38:2444-2452.
69. Huang S.Y., Murai J., Dalla Rosa I., Dexheimer T.S., Naumova A., Gmeiner W.H., Pommier Y. TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs. Nucleic Acids Res. 2013, 41:7793-7803.
70. Raymond A.C., Rideout M.C., Staker B., Hjerrild K., Burgin A.B. Analysis of human tyrosyl-DNA phosphodiesterase I catalytic residues. J. Mol. Biol. 2004, 338:895-906.
71. Rideout M.C., Raymond A.C., Burgin A.B. Design and synthesis of fluorescent substrates for human tyrosyl-DNA phosphodiesterase I. Nucleic Acids Res. 2004, 32:4657-4664.
72. Antony S., Marchand C., Stephen A.G., Thibaut L., Agama K.K., Fisher R.J., Pommier Y. Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1. Nucleic Acids Res. 2007, 35:4474-4484.
73. Interthal H., Pouliot J.J., Champoux J.J. The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proc. Nat. Acad. Sci. U.S.A. 2001, 98:12009-12014.
74. Davies D.R., Interthal H., Champoux J.J., Hol W.G. The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1. Structure 2002, 10:237-248.
75. Davies D.R., Interthal H., Champoux J.J., Hol W.G. Crystal structure of a transition state mimic for Tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide. Chem. Biol. 2003, 10:139-147.
76. Porter S.E., Champoux J.J. Mapping in vivo topoisomerase I sites on simian virus 40 DNA: asymmetric distribution of sites on replicating molecules. Mol. Cell Biol. 1989, 9:541-550.
77. Jaxel C., Capranico G., Kerrigan D., Kohn K.W., Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 1991, 266:20418-20423.
78. Plo I., Liao Z.Y., Barcelo J.M., Kohlhagen G., Caldecott K.W., Weinfeld M., Pommier Y. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst.) 2003, 2:1087-1100.
79. Takashima H., Boerkoel C.F., John J., Saifi G.M., Salih M.A., Armstrong D., Mao Y., Quiocho F.A., Roa B.B., Nakagawa M., Stockton D.W., Lupski J.R. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat. Genet. 2002, 32:267-272.
80. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem. Sci. 2006, 31:402-410.
81. Shiloh Y., Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 2013, 14:197-210.
82. Lee J.H., Paull T.T. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007, 26:7741-7748.
83. Cimprich K.A., Cortez D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 2008, 9:616-627.
84. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421:499-506.
85. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R., Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
86. Weterings E., Chen D.J. DNA-dependent protein kinase in nonhomologous end joining: a lock with multiple keys?. J. Cell. Biol. 2007, 179:183-186.
87. Solier S., Kohn K.W., Scroggins B., Xu W., Trepel J., Neckers L., Pommier Y. Feature article: heat shock protein 90alpha (HSP90alpha), a substrate and chaperone of DNA-PK necessary for the apoptotic response. Proc. Nat. Acad. Sci. U.S.A. 2012, 109:12866-12872.
88. Das B.B., Antony S., Gupta S., Dexheimer T.S., Redon C.E., Garfield S., Shiloh Y., Pommier Y. Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA-PK. EMBO J. 2009, 28:3667-3680.
89. Chiang S.C., Carroll J., El-Khamisy S.F. TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage. Cell Cycle 2010, 9:588-595.
90. Mani R.S., Fanta M., Karimi-Busheri F., Silver E., Virgen C.A., Caldecott K.W., Cass C.E., Weinfeld M. XRCC1 stimulates polynucleotide kinase by enhancing its damage discrimination and displacement from DNA repair intermediates. J. Biol. Chem. 2007, 282:28004-28013.
91. Caldecott K.W. Single-strand break repair and genetic disease. Nat. Rev. Genet. 2008, 9:619-631.
92. Audebert M., Salles B., Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J. Biol. Chem. 2004, 279:55117-55126.
93. Rosidi B., Wang M., Wu W., Sharma A., Wang H., Iliakis G. Histone H1 functions as a stimulatory factor in backup pathways of NHEJ. Nucleic Acids Res. 2008, 36:1610-1623.
94. Nocentini S. Rejoining kinetics of DNA single- and double-strand breaks in normal and DNA ligase-deficient cells after exposure to ultraviolet C and gamma radiation: an evaluation of ligating activities involved in different DNA repair processes. Radiat. Res. 1999, 151:423-432.
95. Rosell R., Skrzypski M., Jassem E., Taron M., Bartolucci R., Sanchez J.J., Mendez P., Chaib I., Perez-Roca L., Szymanowska A., Rzyman W., Puma F., Kobierska-Gulida G., Farabi R., Jassem J. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2007, 2:e1129.
96. Pommier Y., Barcelo J.M., Rao V.A., Sordet O., Jobson A.G., Thibaut L., Miao Z.H., Seiler J.A., Zhang H., Marchand C., Agama K., Nitiss J.L., Redon C. Repair of topoisomerase I-mediated DNA damage. Prog. Nucleic Acid Res. Mol. Biol. 2006, 81:179-229.
97. D'Onofrio G., Tramontano F., Dorio A.S., Muzi A., Maselli V., Fulgione D., Graziani G., Malanga M., Quesada P. Poly(Adp-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells. Biochem. Pharmacol. 2010.
98. Horton J.K., Watson M., Stefanick D.F., Shaughnessy D.T., Taylor J.A., Wilson S.H. XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008, 18:48-63.
99. Chou W.C., Wang H.C., Wong F.H., Ding S.L., Wu P.E., Shieh S.Y., Shen C.Y. Chk2-dependent phosphorylation of XRCC1 in the DNA damage response promotes base excision repair. EMBO J. 2008, 27:3140-3150.
100. Levy N., Martz A., Bresson A., Spenlehauer C., de Murcia G., Menissier-de Murcia J. XRCC1 is phosphorylated by DNA-dependent protein kinase in response to DNA damage. Nucleic Acids Res. 2006, 34:32-41.
101. Toulany M., Dittmann K., Fehrenbacher B., Schaller M., Baumann M., Rodemann H.P. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. DNA Repair (Amst.) 2008, 7:1746-1756.
102. Strumberg D., Pilon A.A., Smith M., Hickey R., Malkas L., Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell Biol. 2000, 20:3977-3987.
103. Furuta T., Takemura H., Liao Z.Y., Aune G.J., Redon C., Sedelnikova O.A., Pilch D.R., Rogakou E.P., Celeste A., Chen H.T., Nussenzweig A., Aladjem M.I., Bonner W.M., Pommier Y. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 2003, 278:20303-20312.
104. Seiler J.A., Conti C., Syed A., Aladjem M.I., Pommier Y. The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol. Cell Biol. 2007, 27:5806-5818.
105. Hudson J.J., Chiang S.C., Wells O.S., Rookyard C., El-Khamisy S.F. SUMO modification of the neuroprotective protein TDP1 facilitates chromosomal single-strand break repair. Nat. Commun. 2012, 3:733.
106. Flotho A., Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu. Rev. Biochem. 2013, 82:357-385.
107. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 2007, 8:947-956.
108. Mao Y., Sun M., Desai S.D., Liu L.F. SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. Proc. Nat. Acad. Sci. U.S.A. 2000, 97:4046-4051.
109. Horie K., Tomida A., Sugimoto Y., Yasugi T., Yoshikawa H., Taketani Y., Tsuruo T. SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin. Oncogene 2002, 21:7913-7922.
110. Lin C.P., Ban Y., Lyu Y.L., Desai S.D., Liu L.F. A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. J. Biol. Chem. 2008, 283:21074-21083.
111. Desai S.D., Li T.K., Rodriguez-Bauman A., Rubin E.H., Liu L.F. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001, 61:5926-5932.
112. Heideker J., Prudden J., Perry J.J., Tainer J.A., Boddy M.N. SUMO-targeted ubiquitin ligase, Rad60, and Nse2 SUMO ligase suppress spontaneous Top1-mediated DNA damage and genome instability. PLos Genet. 2011, 7:e1001320.
113. Das B.B., Huang S.N., Murai J., Rehman I., Amé J.-C., Sengupta S., Das S.K., Majumdar P., Zhang H., Biard D., Majumder H.K., Schreiber V., Pommier Y. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucl. Acids Res. 2014, 42:4435-4449.
114. Patel A.G., Flatten K.S., Schneider P.A., Dai N.T., McDonald J.S., Poirier G.G., Kaufmann S.H. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J. Biol. Chem. 2012, 287:4198-4210.
115. Bowman K.J., Newell D.R., Calvert A.H., Curtin N.J. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br. J. Cancer 2001, 84:106-112.
116. Ray Chaudhuri A., Hashimoto Y., Herrador R., Neelsen K.J., Fachinetti D., Bermejo R., Cocito A., Costanzo V., Lopes M. Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat. Struct. Mol. Biol. 2012, 19:419-423.
117. Sugimura K., Takebayashi S., Taguchi H., Takeda S., Okumura K. PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J. Cell. Biol. 2008, 183:1203-1212.
118. Berti M., Chaudhuri A.R., Thangavel S., Gomathinayagam S., Kenig S., Vujanovic M., Odreman F., Glatter T., Graziano S., Mendoza-Maldonado R., Marino F., Lucic B., Biasin V., Gstaiger M., Aebersold R., Sidorova J.M., Monnat R.J., Lopes M., Vindigni A. Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition. Nat. Struct. Mol. Biol. 2013, 20:347-354.
119. Schreiber V., Dantzer F., Ame J.C., de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7:517-528.
120. Hottiger M.O., Hassa P.O., Luscher B., Schuler H., Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci. 2010, 35:208-219.
121. Ledesma F.C., El Khamisy S.F., Zuma M.C., Osborn K., Caldecott K.W. A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 2009, 461:674-678.
122. Pype S., Declercq W., Ibrahimi A., Michiels C., Van Rietschoten J.G., Dewulf N., de Boer M., Vandenabeele P., Huylebroeck D., Remacle J.E. TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa B activation. J. Biol. Chem. 2000, 275:18586-18593.
123. Rodrigues-Lima F., Josephs M., Katan M., Cassinat B. Sequence analysis identifies TTRAP, a protein that associates with CD40 and TNF receptor-associated factors, as a member of a superfamily of divalent cation-dependent phosphodiesterases. Biochem.Biophys. Res. Commun. 2001, 285:1274-1279.
124. Virgen-Slane R., Rozovics J.M., Fitzgerald K.D., Ngo T., Chou W., van der Heden van Noort G.J., Filippov D.V., Gershon P.D., Semler B.L. An RNA virus hijacks an incognito function of a DNA repair enzyme. Proc. Nat. Acad. Sci. U.S.A. 2012, 109:14634-14639.
125. Pei H., Yordy J.S., Leng Q., Zhao Q., Watson D.K., Li R. EAPII interacts with ETS1 and modulates its transcriptional function. Oncogene 2003, 22:2699-2709.
126. Varady G., Sarkadi B., Fatyol K. TTRAP is a novel component of the non-canonical TRAF6-TAK1 TGF-beta signaling pathway. PLoS One 2011, 6:e25548.
127. Li C., Fan S., Owonikoko T.K., Khuri F.R., Sun S.Y., Li R. Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene 2011, 30:3802-3812.
128. Do P.M., Varanasi L., Fan S., Li C., Kubacka I., Newman V., Chauhan K., Daniels S.R., Boccetta M., Garrett M.R., Li R., Martinez L.A. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev. 2012, 26:830-845.
129. Cortes Ledesma F., El Khamisy S.F., Zuma M.C., Osborn K., Caldecott K.W. A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 2009, 461:674-678.
130. Zeng Z., Cortes-Ledesma F., El-Khamisy S.F., Caldecott K.W. TDP2/TTRAP is the major 5'-tyrosyl DNA phosphodiesterase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage. J. Biol. Chem. 2010, 286:403-409.
131. Gomez-Herreros F., Schuurs-Hoeijmakers J.H., McCormack M., Greally M.T., Rulten S., Romero-Granados R., Counihan T.J., Chaila E., Conroy J., Ennis S., Delanty N., Cortes-Ledesma F., de Brouwer A.P., Cavalleri G.L., El-Khamisy S.F., de Vries B.B., Caldecott K.W. TDP2 protects transcription from abortive topoisomerase activity and is required for normal neural function. Nat. Genet. 2014, 46:516-521.
132. Gomez-Herreros F., Romero-Granados R., Zeng Z., Alvarez-Quilon A., Quintero C., Ju L., Umans L., Vermeire L., Huylebroeck D., Caldecott K.W., Cortes-Ledesma F. TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo. PLoS Genet. 2013, 9:e1003226.
133. Zeng Z., Sharma A., Ju L., Murai J., Umans L., Vermeire L., Pommier Y., Takeda S., Huylebroeck D., Caldecott K.W., El-Khamisy S.F. TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1. Nucleic Acids Res. 2012, 40:8371-8380.
134. 2+-dependent phosphodiesterase specific for the repair of topoisomerase cleavage complexes. J. Biol. Chem. 2012, 287:30842-30852.
135. Ambros V., Baltimore D. Protein is linked to the 5' end of poliovirus RNA by a phosphodiester linkage to tyrosine. J. Biol. Chem. 1978, 253:5263-5266.
136. Schellenberg M.J., Appel C.D., Adhikari S., Robertson P.D., Ramsden D.A., Williams R.S. Mechanism of repair of 5'-topoisomerase II-DNA adducts by mammalian tyrosyl-DNA phosphodiesterase 2. Nat. Struct. Mol. Biol. 2012, 19:1363-1371.
137. Shi K., Kurahashi K., Gao R., Tsutakawa S.E., Tainer J.A., Pommier Y., Aihara H. Structural basis for recognition of 5'-phosphotyrosine adducts by Tdp2. Nat. Struct. Mol. Biol. 2012, 19:1372-1377.
138. Adhikari S., Karmahapatra S., Karve T., Bandyopadhyay S., Woodrick J., Manthena P., Glasgow E., Byers S., Saha T., Uren A. Characterization of magnesium requirement of human 5'-tyrosyl DNA phosphodiesterase mediated reaction. BMC Res. (Notes) 2012, 5:134.
139. Nitiss J.L., Nitiss K.C. Tdp2: a means to fixing the ends. PLoS Genet. 2013, 9:e1003370.
140. Nitiss J., Soans E., Berk J., Seth A., Mishina M., Nitiss K.C. Repair of topoisomerase II-mediated DNA damage: fixing DNA damage arising from a protein covalently trapped on DNA. DNA Topoisomerases and Cancer 2012, 381-407. Springer Humana Press, New York, NY. Y. Pommier (Ed.).
141. Mao Y., Desai S.D., Ting C.Y., Hwang J.L., Liu L.F. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J. Biol. Chem. 2001, 276:40652-40658.
142. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
143. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
144. Turner N.C., Lord C.J., Iorns E., Brough R., Swift S., Elliott R., Rayter S., Tutt A.N., Ashworth A. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008, 27:1368-1377.
145. Curtin N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 2012, 12:801-817.
146. Malik M., Nitiss J.L. DNA repair functions that control sensitivity to topoisomerase-targeting drugs. Eukaryotic Cell 2004, 3:82-90.
147. Deng C., Brown J.A., You D., Brown J.M. Multiple endonucleases function to repair covalent topoisomerase I complexes in Saccharomyces cerevisiae. Genetics 2005, 170:591-600.
148. Sacho E.J., Maizels N. DNA repair factor MRE11/RAD50 cleaves 3'-phosphotyrosyl bonds and resects DNA to repair damage caused by topoisomerase 1 poisons. J. Biol. Chem. 2011, 286:44945-44951.
149. Nakamura K., Kogame T., Oshiumi H., Shinohara A., Sumitomo Y., Agama K., Pommier Y., Tsutsui K.M., Tsutsui K., Hartsuiker E., Ogi T., Takeda S., Taniguchi Y. Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair. PLoS Genet. 2010, 6:e1000828.
150. Sartori A.A., Lukas C., Coates J., Mistrik M., Fu S., Bartek J., Baer R., Lukas J., Jackson S.P. Human CtIP promotes DNA end resection. Nature 2007, 450:509-514.
151. Giannini G., Rinaldi C., Ristori E., Ambrosini M.I., Cerignoli F., Viel A., Bidoli E., Berni S., D'Amati G., Scambia G., Frati L., Screpanti I., Gulino A. Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene 2004, 23:2640-2647.
152. Marchand C., Lea W.A., Jadhav A., Dexheimer T.S., Austin C.P., Inglese J., Pommier Y., Simeonov A. Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay. Mol. Cancer Ther. 2009, 8:240-248.
153. Adhikari S., Karmahapatra S.K., Elias H., Dhopeshwarkar P., Williams R.S., Byers S., Uren A., Roy R. Development of a novel assay for human tyrosyl DNA phosphodiesterase 2. Anal. Biochem. 2011, 416:112-116.
154. Thomson G., Watson A., Caldecott K., Denneny O., Depledge P., Hamilton N., Hopkins G., Jordan A., Morrow C., Raoof A., Waddell I., Ogilvie D. Generation of assays and antibodies to facilitate the study of human 5'-tyrosyl DNA phosphodiesterase. Anal. Biochem. 2013, 436:145-150.
155. Raoof A., Depledge P., Hamilton N.M., Hamilton N.S., Hitchin J.R., Hopkins G.V., Jordan A.M., Maguire L.A., McGonagle A.E., Mould D.P., Rushbrooke M., Small H.F., Smith K.M., Thomson G.J., Turlais F., Waddell I.D., Waszkowycz B., Watson A.J., Ogilvie D.J. Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II. J. Med. Chem. 2013, 56:6352-6370.
156. Liao Z., Thibaut L., Jobson A., Pommier Y. Inhibition of human tyrosyl-DNA phosphodiesterase by aminoglycoside antibiotics and ribosome inhibitors. Mol. Pharmacol. 2006, 70:366-372.
157. Dexheimer T.S., Gediya L.K., Stephen A.G., Weidlich I., Antony S., Marchand C., Interthal H., Nicklaus M., Fisher R.J., Njar V.C., Pommier Y. 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors. J. Med. Chem. 2009, 52:7122-7131.
158. Conda-Sheridan M., Reddy P.V., Morrell A., Cobb B.T., Marchand C., Agama K., Chergui A., Renaud A., Stephen A.G., Bindu L.K., Pommier Y., Cushman M. Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1). J. Med. Chem. 2013, 56:182-200.
159. Nguyen T.X., Morrell A., Conda-Sheridan M., Marchand C., Agama K., Bermingham A., Stephen A.G., Chergui A., Naumova A., Fisher R., O'Keefe B.R., Pommier Y., Cushman M. Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors. J. Med. Chem. 2012, 55:4457-4478.
160. Sirivolu V.R., Vernekar S.K., Marchand C., Naumova A., Chergui A., Renaud A., Stephen A.G., Chen F., Sham Y.Y., Pommier Y., Wang Z. 5-Arylidenethioxothiazolidinones as inhibitors of tyrosyl-DNA phosphodiesterase I. J. Med. Chem. 2012, 55:8671-8684.
161. Kim Y., Spitz G.S., Veturi U., Lach F.P., Auerbach A.D., Smogorzewska A. Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. Blood 2013, 121:54-63.
162. Hartsuiker E., Neale M.J., Carr A.M. Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA. Mol. Cell 2009, 33:117-123.
163. Pourquier P., Pommier Y. Topoisomerase I-mediated DNA damage. Adv. Cancer Res. 2001, 80:189-216.
164. Sordet O., Khan Q.A., Pommier Y. Apoptotic topoisomerase I-DNA complexes induced by oxygen radicals and mitochondrial dysfunction. Cell Cycle 2004, 3:1095-1097.
165. Pourquier P., Ueng L.-M., Kohlhagen G., Mazumder A., Gupta M., Kohn K.W., Pommier Y. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol. Chem. 1997, 272:7792-7796.
166. Lesher D.T., Pommier Y., Stewart L., Redinbo M.R. 8-Oxoguanine rearranges the active site of human topoisomerase I. Proc. Nat. Acad. Sci. U.S.A. 2002, 99:12102-12107.
167. Wang X., Henningfeld K.A., Hecht S.M. DNA topoisomerase I-mediated formation of structurally modified DNA duplexes, effects of metal ions and topoisomerase I inhibitors. Biochemistry 1998, 37:2691-2700.
168. Leteurtre F., Kohlhagen G., Fesen M.R., Tanizawa A., Kohn K.W., Pommier Y. Effects of DNA methylation on topoisomerase I and II cleavage activities. J. Biol. Chem. 1994, 269:7893-7900.
169. Antony S., Arimondo P.B., Sun J.S., Pommier Y. Position- and orientation-specific enhancement of topoisomerase I cleavage complexes by triplex DNA structures. Nucleic Acids Res. 2004, 32:5163-5173.
170. Sordet O., Khan Q., Kohn K.W., Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anticancer Agents 2003, 3:271-290.
171. Sordet O., Khan Q.A., Plo I., Pourquier P., Urasaki Y., Yoshida A., Antony S., Kohlhagen G., Solary E., Saparbaev M., Laval J., Pommier Y. Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals. J. Biol. Chem. 2004, 279:50499-50504.
172. Sordet O., Liao Z., Liu H., Antony S., Stevens E.V., Kohlhagen G., Fu H., Pommier Y. Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis. J. Biol. Chem. 2004, 279:33968-33975.
173. Lanza A., Tornatelli S., Rodolfo C., Scanavini M.C., Pedrini A.M. Human DNA topoisomerase I-mediated cleavages stimulated by ultraviolet light-induced DNA damage. J. Biol. Chem. 1996, 271:6978-6986.
174. Subramanian D., Rosenstein B.S., Muller M.T. Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation in vivo: possible relationship with DNA repair. Cancer Res. 1998, 58:976-984.
175. Pourquier P., Waltman J.L., Urasaki Y., Loktionova N.A., Pegg A.E., Nitiss J.L., Pommier Y. Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res. 2001, 61:53-58.
176. Pommier Y., Laco G.S., Kohlhagen G., Sayer J.M., Kroth H., Jerina D.M. Position-specific trapping of topoisomerase I-DNA cleavage complexes by intercalated benzo[a]-pyrene diol epoxide adducts at the 6-amino group of adenine. Proc. Nat. Acad. Sci. U.S.A. 2000, 97:10739-10744.
177. Pommier Y., Kohlhagen G., Pourquier P., Sayer J.M., Kroth H., Jerina D.M. Benzo[a]pyrene epoxide adducts in DNA are potent inhibitors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages. Proc. Nat. Acad. Sci. U.S.A. 2000, 97:2040-2045.
178. Pommier Y., Kohlhagen G., Laco G.S., Kroth H., Sayer J.M., Jerina D.M. Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site. J. Biol. Chem. 2002, 277:13666-13672.
179. Pourquier P., Bjornsti M.-A., Pommier Y. Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct, 1,N6-ethenoadenine. J. Biol. Chem. 1998, 273:27245-27249.
180. Antony S., Theruvathu J.A., Brooks P.J., Lesher D.T., Redinbo M., Pommier Y. Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2'-deoxyguanosine. Nucleic Acids Res. 2004, 32:5685-5692.
181. Dexheimer T.S., Kozekova A., Rizzo C.J., Stone M.P., Pommier Y. The modulation of topoisomerase I-mediated DNA cleavage and the induction of DNA-topoisomerase I crosslinks by crotonaldehyde-derived DNA adducts. Nucleic Acids Res. 2008, 36:4128-4136.
182. Kingma P.S., Osheroff N. The response of eukaryotic topoisomerases to DNA damage. Biochim. Biophys. Acta 1998, 1400:223-232.
183. Kingma P.S., Burden D.A., Osheroff N. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance. Biochemistry 1999, 38:3457-3461.
184. Kingma P.S., Greider C.A., Osheroff N. Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochemistry 1997, 36:5934-5939.
185. Sabourin M., Osheroff N. Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res. 2000, 28:1947-1954.
186. Velez-Cruz R., Riggins J.N., Daniels J.S., Cai H., Guengerich F.P., Marnett L.J., Osheroff N. Exocyclic DNA lesions stimulate DNA cleavage mediated by human topoisomerase II alpha in vitro and in cultured cells. Biochemistry 2005, 44:3972-3981.
187. Wilstermann A.M., Osheroff N. Base excision repair intermediates as topoisomerase II poisons. J. Biol. Chem. 2001, 276:46290-46296.
188. Kingma P.S., Osheroff N. Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage. J. Biol. Chem. 1997, 272:7488-7493.
189. Bigioni M., Zunino F., Capranico G. Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage. Nucleic Acids Res. 1994, 22:2274-2281.
190. Wang Y., Knudsen B.R., Bjergbaek L., Westergaard O., Andersen A.H. Stimulated activity of human topoisomerases IIalpha and IIbeta on RNA-containing substrates. J. Biol. Chem. 1999, 274:22839-22846.
191. Wang Y., Thyssen A., Westergaard O., Andersen A.H. Position-specific effect of ribonucleotides on the cleavage activity of human topoisomerase II. Nucleic Acids Res. 2000, 28:4815-4821.
192. Deweese J.E., Burgin A.B., Osheroff N. Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha. Biochemistry 2008, 47:4129-4140.
193. Deweese J.E., Osheroff N. Coordinating the two protomer active sites of human topoisomerase IIalpha: nicks as topoisomerase II poisons. Biochemistry 2009, 48:1439-1441.
194. Corbett A.H., Zechiedrich E.L., Lloyd R.S., Osheroff N. Inhibition of eukaryotic topoisomerase II by ultraviolet-induced cyclobutane pyrimidine dimers. J. Biol. Chem. 1991, 266:19666-19671.
195. Cline S.D., Osheroff N. Cytosine arabinoside (araC) lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes. J. Biol. Chem. 1999, 274:29740-29743.
196. Khan Q.A., Kohlhagen G., Marshall R., Austin C.A., Kalena G.P., Kroth H., Sayer J.M., Jerina D.M., Pommier Y. Position-specific trapping of topoisomerase II by benzo[a]pyrene diol epoxide adducts: implications for interactions with intercalating anticancer agents. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:12498-12503.
197. Francks C., Paracchini S., Smith S.D., Richardson A.J., Scerri T.S., Cardon L.R., Marlow A.J., MacPhie I.L., Walter J., Pennington B.F., Fisher S.E., Olson R.K., DeFries J.C., Stein J.F., Monaco A.P. A 77-kilobase region of chromosome 6p22.2 is associated with dyslexia in families from the United Kingdom and from the United States. Am. J. Hum. Genet. 2004, 75:1046-1058.
198. Paracchini S., Thomas A., Castro S., Lai C., Paramasivam M., Wang Y., Keating B.J., Taylor J.M., Hacking D.F., Scerri T., Francks C., Richardson A.J., Wade-Martins R., Stein J.F., Knight J.C., Copp A.J., Loturco J., Monaco A.P. The chromosome 6p22 haplotype associated with dyslexia reduces the expression of KIAA0319, a novel gene involved in neuronal migration. Hum. Mol. Genet. 2006, 15:1659-1666.
199. Cope N., Harold D., Hill G., Moskvina V., Stevenson J., Holmans P., Owen M.J., O'Donovan M.C., Williams J. Strong evidence that KIAA0319 on chromosome 6p is a susceptibility gene for developmental dyslexia. Am. J. Hum. Genet. 2005, 76:581-591.
200. Vilotti S., Codrich M., Dal Ferro M., Pinto M., Ferrer I., Collavin L., Gustincich S., Zucchelli S. Parkinson's disease DJ-1 L166P alters rRNA biogenesis by exclusion of TTRAP from the nucleolus and sequestration into cytoplasmic aggregates via TRAF6. PLoS One 2012, 7:e35051.
201. Vilotti S., Biagioli M., Foti R., Dal Ferro M., Lavina Z.S., Collavin L., Del Sal G., Zucchelli S., Gustincich S. The PML nuclear bodies-associated protein TTRAP regulates ribosome biogenesis in nucleolar cavities upon proteasome inhibition. Cell Death Differ. 2012, 19:488-500.
202. Zucchelli S., Vilotti S., Calligaris R., Lavina Z.S., Biagioli M., Foti R., De Maso L., Pinto M., Gorza M., Speretta E., Casseler C., Tell G., Del Sal G., Gustincich S. Aggresome-forming TTRAP mediates pro-apoptotic properties of Parkinson's disease-associated DJ-1 missense mutations. Cell Death Differ. 2009, 16:428-438.
203. Hawkins A.J., Subler M.A., Akopiants K., Wiley J.L., Taylor S.M., Rice A.C., Windle J.J., Valerie K., Povirk L.F. In vitro complementation of Tdp1 deficiency indicates a stabilized enzyme-DNA adduct from tyrosyl but not glycolate lesions as a consequence of the SCAN1 mutation. DNA Repair (Amst.) 2009, 8:654-663.